Abstract: Make a comprehensive analysis about the rhabdomyolysis and elevated liver enzyme induced by simvastatin intermediate-efficacy treatment in our hospital， combined with the existing similar reports.The specific mechanism of simvastatin intermediate-efficacy treatment induce rhabdomyolysis and elevated liver enzymes is still unclear.But combination the drug of inhibition of CYP3A4 activity can increase the risk.The incidence of simvastatin intermediate-efficacy treatment induce rhabdomyolysis and elevated liver enzymes are serious and rare adverse reactions， should be caused the attention of medical institutions， completes the adverse reaction monitoring， achieves safe and effective use of drugs.